-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CSPC's product line welcomes new progress: esomeprazole sodium for injection, a powerful acid-suppressing drug, will be approved, and the new crown mRNA vaccine will be approved for clinical use.
.
.
At present, more than 50 key candidate drugs of CSPC have entered clinical or In the application stage, 2 of them are under review, 3 are ready to be declared for listing, and the pipeline has entered an intensive harvest period; imitation promotes innovation, 69 varieties have been evaluated, 21 varieties have won the bid for centralized procurement, and 11 varieties are preparing for the seventh batch of centralized procurement.
.
.
.
At present, more than 50 key candidate drugs of CSPC have entered clinical or In the application stage, 2 of them are under review, 3 are ready to be declared for listing, and the pipeline has entered an intensive harvest period; imitation promotes innovation, 69 varieties have been evaluated, 21 varieties have won the bid for centralized procurement, and 11 varieties are preparing for the seventh batch of centralized procurement.
.
Win 3 major varieties! Sprint 3.
3 billion injections
3 billion injections
Recently, CSPC entered the administrative examination and approval stage for the production of 4 types of imitation esomeprazole sodium for injection
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease , erosive reflux esophagitis,
etc.
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease , erosive reflux esophagitis,
etc.
According to data from Minet.
com, the domestic market of esomeprazole injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 3.
3 billion yuan; sales in the first half of 2021 are close to 2 billion yuan, a year-on-year increase of 26.
82%
.
com, the domestic market of esomeprazole injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 3.
3 billion yuan; sales in the first half of 2021 are close to 2 billion yuan, a year-on-year increase of 26.
82%
.
Since the beginning of this year, CSPC has approved 3 new products for the market, including lenvatinib mesylate capsules, mitoxantrone hydrochloride liposome injection, and duvelise capsules
.
Esomeprazole sodium for injection is expected to become the company's fourth product approved for marketing this year
.
.
Esomeprazole sodium for injection is expected to become the company's fourth product approved for marketing this year
.
Products approved by CSPC from 2022 to the present
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Among the 3 new products, Duvelise Capsule is the world's first approved oral dual inhibitor of PI3K-delta and PI3K-gamma, and the first PI3K selective inhibitor approved in China; mitoxantrone hydrochloride lipid Body injection is a broad-spectrum anti-tumor nano-drug, the world's first marketed mitoxantrone nano-drug for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL); lenvatinib mesylate capsules are An oral multi-target tyrosine kinase inhibitor to be included in the seventh batch of centralized collection catalog
.
.
69 varieties have been reviewed! 11 varieties prepare for the seventh batch of centralized procurement
Since the beginning of this year, CSPC has reviewed 3 varieties, including lenvatinib mesylate capsules, lidocaine hydrochloride injection and biapenem for injection
.
Up to now, CSPC has a total of 69 varieties (105 specifications) that have passed/deemed to pass the consistency evaluation
.
.
Up to now, CSPC has a total of 69 varieties (105 specifications) that have passed/deemed to pass the consistency evaluation
.
In terms of therapeutic areas, the 69 varieties are mainly systemic antibacterial drugs (20), antitumor drugs (10), diabetes drugs (7) and antithrombotic drugs (6)
.
.
21 varieties are the first to be reviewed by CSPC, including ranitidine hydrochloride capsules, cefadroxil tablets, glimepiride dispersible tablets, dipyridamole tablets, nintedanib ethanesulfonate soft capsules, amphoteric for injection Seven varieties including Mycin B Cholesterol Sulfate Complex and Doxorubicin Hydrochloride Liposome Injection are exclusively reviewed
.
.
CSPC passed/deemed to pass the consistency evaluation varieties
Source: Minet Consistency Evaluation Database
Among the first five batches of centralized procurement carried out by the state, CSPC won the bid for 1, 2, 9, 6 and 3 varieties respectively, with a total of 21 varieties
.
In the upcoming seventh batch of centralized procurement, CSPC has won admission tickets for 11 varieties
.
.
In the upcoming seventh batch of centralized procurement, CSPC has won admission tickets for 11 varieties
.
The competition pattern of the seventh batch of products proposed by CSPC
Source: Mi intranet database
Among the 11 varieties to be collected, the generic drugs involved in 5 varieties will have terminal sales of more than 1 billion yuan in China's public medical institutions in 2020; the competition of many varieties is becoming more intense, and there are 10 or more competing generic drugs.
There are 5
.
It is worth noting that the market share of the 10 proposed centralized procurement varieties is relatively low or blank.
If the centralized procurement is successful, the market will be opened quickly, and the company will be more willing to lower prices
.
There are 5
.
It is worth noting that the market share of the 10 proposed centralized procurement varieties is relatively low or blank.
If the centralized procurement is successful, the market will be opened quickly, and the company will be more willing to lower prices
.
R&D investment of 3.
433 billion, 50 key drug candidates
433 billion, 50 key drug candidates
In recent years, CSPC has implemented a development strategy centered on innovation and continued to increase investment in research and development
.
In 2021, CSPC's research and development expenses will be 3.
433 billion yuan, a year-on-year increase of 18.
78%, and its research and development investment is at the forefront of domestic pharmaceutical companies
.
With huge investment, CSPC has built a rich pipeline of products under research
.
.
In 2021, CSPC's research and development expenses will be 3.
433 billion yuan, a year-on-year increase of 18.
78%, and its research and development investment is at the forefront of domestic pharmaceutical companies
.
With huge investment, CSPC has built a rich pipeline of products under research
.
Research and development expenses of CSPC (unit: 100 million yuan)
Source: Company Annual Report
At the same time, CSPC has deployed R&D centers around the world, with eight innovative research platforms including monoclonal antibody, double antibody, nano-drug, small molecule new drug screening and R&D, ADC, siRNA, mRNA, and PROTAC
.
Using the newly established nucleic acid drug development platform, CSPC is advancing research on mRNA vaccines against various strains including Delta and Omicron
.
.
Using the newly established nucleic acid drug development platform, CSPC is advancing research on mRNA vaccines against various strains including Delta and Omicron
.
On April 3, CSPC announced that the new coronavirus mRNA vaccine SYS6006 developed by the company has been approved for clinical research in China
.
The product is designed with targeted antigenic mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immune protection efficacy against the current mainstream mutant strains including Omicron and Delta; through humoral immunity and cellular immunity The body provides immune protection and can produce memory B cells to provide long-lasting protection
.
.
The product is designed with targeted antigenic mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immune protection efficacy against the current mainstream mutant strains including Omicron and Delta; through humoral immunity and cellular immunity The body provides immune protection and can produce memory B cells to provide long-lasting protection
.
In terms of BD, CSPC has also achieved a lot.
In 2021, it will complete 6 product license introduction, cooperation and acquisition projects, involving products in multiple therapeutic areas
.
In terms of external authorization, the subsidiary NovaRock's innovative drug NBL-015 (Claudin18.
2 monoclonal antibody) has reached a cooperation with Flame Biosciences of the United States, which is an important milestone for CSPC's innovative drugs to go overseas
.
In 2021, it will complete 6 product license introduction, cooperation and acquisition projects, involving products in multiple therapeutic areas
.
In terms of external authorization, the subsidiary NovaRock's innovative drug NBL-015 (Claudin18.
2 monoclonal antibody) has reached a cooperation with Flame Biosciences of the United States, which is an important milestone for CSPC's innovative drugs to go overseas
.
At present, CSPC has about 300 research projects, including more than 40 small molecule innovative drugs, more than 40 macromolecule innovative drugs, and more than 30 new preparations, mainly focusing on tumors, immunity, respiration, neuropsychiatry, metabolism, cardiac Cerebrovascular system and anti-infective therapy
.
The company expects that more than 30 innovative drugs and new preparation products and more than 60 generic drugs will be launched in the next five years
.
.
The company expects that more than 30 innovative drugs and new preparation products and more than 60 generic drugs will be launched in the next five years
.
CSPC's key drug candidates
Source: CSPC
Among the research projects, more than 50 key drug candidates have entered the clinical or application stage
.
Among them, 13 have entered the key clinical trial stage; Rezetinib mesylate capsules (third-generation EGFR-TKI) and desvenlafaxine succinate sustained-release tablets have submitted NDAs and are expected to be approved for marketing in 2022 ; Amphotericin B liposome and irinotecan liposome injection for nano-drug injection, RANKL monoclonal antibody JMT103 will be declared for listing soon
.
.
Among them, 13 have entered the key clinical trial stage; Rezetinib mesylate capsules (third-generation EGFR-TKI) and desvenlafaxine succinate sustained-release tablets have submitted NDAs and are expected to be approved for marketing in 2022 ; Amphotericin B liposome and irinotecan liposome injection for nano-drug injection, RANKL monoclonal antibody JMT103 will be declared for listing soon
.
Data source: Minet database, company announcement
Note: The statistics are as of April 10.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Recently, CSPC's product line welcomes new progress: esomeprazole sodium for injection, a powerful acid-suppressing drug, will be approved, and the new crown mRNA vaccine will be approved for clinical use.
.
.
At present, more than 50 key candidate drugs of CSPC have entered clinical or In the application stage, 2 of them are under review, 3 are ready to be declared for listing, and the pipeline has entered an intensive harvest period; imitation promotes innovation, 69 varieties have been evaluated, 21 varieties have won the bid for centralized procurement, and 11 varieties are preparing for the seventh batch of centralized procurement.
.
.
.
At present, more than 50 key candidate drugs of CSPC have entered clinical or In the application stage, 2 of them are under review, 3 are ready to be declared for listing, and the pipeline has entered an intensive harvest period; imitation promotes innovation, 69 varieties have been evaluated, 21 varieties have won the bid for centralized procurement, and 11 varieties are preparing for the seventh batch of centralized procurement.
.
Win 3 major varieties! Sprint 3.
3 billion injections
3 billion injections
Recently, CSPC entered the administrative examination and approval stage for the production of 4 types of imitation esomeprazole sodium for injection
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease , erosive reflux esophagitis,
etc.
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease , erosive reflux esophagitis,
etc.
According to data from Minet.
com, the domestic market of esomeprazole injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 3.
3 billion yuan; sales in the first half of 2021 are close to 2 billion yuan, a year-on-year increase of 26.
82%
.
com, the domestic market of esomeprazole injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 3.
3 billion yuan; sales in the first half of 2021 are close to 2 billion yuan, a year-on-year increase of 26.
82%
.
Since the beginning of this year, CSPC has approved 3 new products for the market, including lenvatinib mesylate capsules, mitoxantrone hydrochloride liposome injection, and duvelise capsules
.
Esomeprazole sodium for injection is expected to become the company's fourth product approved for marketing this year
.
.
Esomeprazole sodium for injection is expected to become the company's fourth product approved for marketing this year
.
Products approved by CSPC from 2022 to the present
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Among the 3 new products, Duvelise Capsule is the world's first approved oral dual inhibitor of PI3K-delta and PI3K-gamma, and the first PI3K selective inhibitor approved in China; mitoxantrone hydrochloride lipid Body injection is a broad-spectrum anti-tumor nano-drug, the world's first marketed mitoxantrone nano-drug for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL); lenvatinib mesylate capsules are An oral multi-target tyrosine kinase inhibitor to be included in the seventh batch of centralized collection catalog
.
.
69 varieties have been reviewed! 11 varieties prepare for the seventh batch of centralized procurement
Since the beginning of this year, CSPC has reviewed 3 varieties, including lenvatinib mesylate capsules, lidocaine hydrochloride injection and biapenem for injection
.
Up to now, CSPC has a total of 69 varieties (105 specifications) that have passed/deemed to pass the consistency evaluation
.
.
Up to now, CSPC has a total of 69 varieties (105 specifications) that have passed/deemed to pass the consistency evaluation
.
In terms of therapeutic areas, the 69 varieties are mainly systemic antibacterial drugs (20), antitumor drugs (10), diabetes drugs (7) and antithrombotic drugs (6)
.
.
21 varieties are the first to be reviewed by CSPC, including ranitidine hydrochloride capsules, cefadroxil tablets, glimepiride dispersible tablets, dipyridamole tablets, nintedanib ethanesulfonate soft capsules, amphoteric for injection Seven varieties including Mycin B Cholesterol Sulfate Complex and Doxorubicin Hydrochloride Liposome Injection are exclusively reviewed
.
.
CSPC passed/deemed to pass the consistency evaluation varieties
Source: Minet Consistency Evaluation Database
Among the first five batches of centralized procurement carried out by the state, CSPC won the bid for 1, 2, 9, 6 and 3 varieties respectively, with a total of 21 varieties
.
In the upcoming seventh batch of centralized procurement, CSPC has won admission tickets for 11 varieties
.
.
In the upcoming seventh batch of centralized procurement, CSPC has won admission tickets for 11 varieties
.
The competition pattern of the seventh batch of products proposed by CSPC
Source: Mi intranet database
Among the 11 varieties to be collected, the generic drugs involved in 5 varieties will have terminal sales of more than 1 billion yuan in China's public medical institutions in 2020; the competition of many varieties is becoming more intense, and there are 10 or more competing generic drugs.
There are 5
.
It is worth noting that the market share of the 10 proposed centralized procurement varieties is relatively low or blank.
If the centralized procurement is successful, the market will be opened quickly, and the company will be more willing to lower prices
.
There are 5
.
It is worth noting that the market share of the 10 proposed centralized procurement varieties is relatively low or blank.
If the centralized procurement is successful, the market will be opened quickly, and the company will be more willing to lower prices
.
R&D investment of 3.
433 billion, 50 key drug candidates
433 billion, 50 key drug candidates
In recent years, CSPC has implemented a development strategy centered on innovation and continued to increase investment in research and development
.
In 2021, CSPC's research and development expenses will be 3.
433 billion yuan, a year-on-year increase of 18.
78%, and its research and development investment is at the forefront of domestic pharmaceutical companies
.
With huge investment, CSPC has built a rich pipeline of products under research
.
.
In 2021, CSPC's research and development expenses will be 3.
433 billion yuan, a year-on-year increase of 18.
78%, and its research and development investment is at the forefront of domestic pharmaceutical companies
.
With huge investment, CSPC has built a rich pipeline of products under research
.
Research and development expenses of CSPC (unit: 100 million yuan)
Source: Company Annual Report
At the same time, CSPC has deployed R&D centers around the world, with eight innovative research platforms including monoclonal antibody, double antibody, nano-drug, small molecule new drug screening and R&D, ADC, siRNA, mRNA, and PROTAC
.
Using the newly established nucleic acid drug development platform, CSPC is advancing research on mRNA vaccines against various strains including Delta and Omicron
.
.
Using the newly established nucleic acid drug development platform, CSPC is advancing research on mRNA vaccines against various strains including Delta and Omicron
.
On April 3, CSPC announced that the new coronavirus mRNA vaccine SYS6006 developed by the company has been approved for clinical research in China
.
The product is designed with targeted antigenic mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immune protection efficacy against the current mainstream mutant strains including Omicron and Delta; through humoral immunity and cellular immunity The body provides immune protection and can produce memory B cells to provide long-lasting protection
.
.
The product is designed with targeted antigenic mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immune protection efficacy against the current mainstream mutant strains including Omicron and Delta; through humoral immunity and cellular immunity The body provides immune protection and can produce memory B cells to provide long-lasting protection
.
In terms of BD, CSPC has also achieved a lot.
In 2021, it will complete 6 product license introduction, cooperation and acquisition projects, involving products in multiple therapeutic areas
.
In terms of external authorization, the subsidiary NovaRock's innovative drug NBL-015 (Claudin18.
2 monoclonal antibody) has reached a cooperation with Flame Biosciences of the United States, which is an important milestone for CSPC's innovative drugs to go overseas
.
In 2021, it will complete 6 product license introduction, cooperation and acquisition projects, involving products in multiple therapeutic areas
.
In terms of external authorization, the subsidiary NovaRock's innovative drug NBL-015 (Claudin18.
2 monoclonal antibody) has reached a cooperation with Flame Biosciences of the United States, which is an important milestone for CSPC's innovative drugs to go overseas
.
At present, CSPC has about 300 research projects, including more than 40 small molecule innovative drugs, more than 40 macromolecule innovative drugs, and more than 30 new preparations, mainly focusing on tumors, immunity, respiration, neuropsychiatry, metabolism, cardiac Cerebrovascular system and anti-infective therapy
.
The company expects that more than 30 innovative drugs and new preparation products and more than 60 generic drugs will be launched in the next five years
.
.
The company expects that more than 30 innovative drugs and new preparation products and more than 60 generic drugs will be launched in the next five years
.
CSPC's key drug candidates
Source: CSPC
Among the research projects, more than 50 key drug candidates have entered the clinical or application stage
.
Among them, 13 have entered the key clinical trial stage; Rezetinib mesylate capsules (third-generation EGFR-TKI) and desvenlafaxine succinate sustained-release tablets have submitted NDAs and are expected to be approved for marketing in 2022 ; Amphotericin B liposome and irinotecan liposome injection for nano-drug injection, RANKL monoclonal antibody JMT103 will be declared for listing soon
.
.
Among them, 13 have entered the key clinical trial stage; Rezetinib mesylate capsules (third-generation EGFR-TKI) and desvenlafaxine succinate sustained-release tablets have submitted NDAs and are expected to be approved for marketing in 2022 ; Amphotericin B liposome and irinotecan liposome injection for nano-drug injection, RANKL monoclonal antibody JMT103 will be declared for listing soon
.
Data source: Minet database, company announcement
Note: The statistics are as of April 10.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Recently, CSPC's product line welcomes new progress: esomeprazole sodium for injection, a powerful acid-suppressing drug, will be approved, and the new crown mRNA vaccine will be approved for clinical use.
.
.
At present, more than 50 key candidate drugs of CSPC have entered clinical or In the application stage, 2 of them are under review, 3 are ready to be declared for listing, and the pipeline has entered an intensive harvest period; imitation promotes innovation, 69 varieties have been evaluated, 21 varieties have won the bid for centralized procurement, and 11 varieties are preparing for the seventh batch of centralized procurement.
.
.
.
At present, more than 50 key candidate drugs of CSPC have entered clinical or In the application stage, 2 of them are under review, 3 are ready to be declared for listing, and the pipeline has entered an intensive harvest period; imitation promotes innovation, 69 varieties have been evaluated, 21 varieties have won the bid for centralized procurement, and 11 varieties are preparing for the seventh batch of centralized procurement.
.
Win 3 major varieties! Sprint 3.
3 billion injections
Win 3 major varieties! Sprint 3. 3 billion injections
3 billion injections
Recently, CSPC entered the administrative examination and approval stage for the production of 4 types of imitation esomeprazole sodium for injection
.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease , erosive reflux esophagitis,
etc.
disease disease disease.
Esomeprazole sodium for injection is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease , erosive reflux esophagitis,
etc.
According to data from Minet.
com, the domestic market of esomeprazole injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 3.
3 billion yuan; sales in the first half of 2021 are close to 2 billion yuan, a year-on-year increase of 26.
82%
.
hospital hospital hospitalcom, the domestic market of esomeprazole injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 3.
3 billion yuan; sales in the first half of 2021 are close to 2 billion yuan, a year-on-year increase of 26.
82%
.
Since the beginning of this year, CSPC has approved 3 new products for the market, including lenvatinib mesylate capsules, mitoxantrone hydrochloride liposome injection, and duvelise capsules
.
Esomeprazole sodium for injection is expected to become the company's fourth product approved for marketing this year
.
.
Esomeprazole sodium for injection is expected to become the company's fourth product approved for marketing this year
.
Products approved by CSPC from 2022 to the present
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Among the 3 new products, Duvelise Capsule is the world's first approved oral dual inhibitor of PI3K-delta and PI3K-gamma, and the first PI3K selective inhibitor approved in China; mitoxantrone hydrochloride lipid Body injection is a broad-spectrum anti-tumor nano-drug, the world's first marketed mitoxantrone nano-drug for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL); lenvatinib mesylate capsules are An oral multi-target tyrosine kinase inhibitor to be included in the seventh batch of centralized collection catalog
.
.
69 varieties have been reviewed! 11 varieties prepare for the seventh batch of centralized procurement
69 varieties have been reviewed! 11 varieties prepare for the seventh batch of centralized procurement Since the beginning of this year, CSPC has reviewed 3 varieties, including lenvatinib mesylate capsules, lidocaine hydrochloride injection and biapenem for injection
.
Up to now, CSPC has a total of 69 varieties (105 specifications) that have passed/deemed to pass the consistency evaluation
.
.
Up to now, CSPC has a total of 69 varieties (105 specifications) that have passed/deemed to pass the consistency evaluation
.
In terms of therapeutic areas, the 69 varieties are mainly systemic antibacterial drugs (20), antitumor drugs (10), diabetes drugs (7) and antithrombotic drugs (6)
.
.
21 varieties are the first to be reviewed by CSPC, including ranitidine hydrochloride capsules, cefadroxil tablets, glimepiride dispersible tablets, dipyridamole tablets, nintedanib ethanesulfonate soft capsules, amphoteric for injection Seven varieties including Mycin B Cholesterol Sulfate Complex and Doxorubicin Hydrochloride Liposome Injection are exclusively reviewed
.
both sexes _.
CSPC passed/deemed to pass the consistency evaluation varieties
Source: Minet Consistency Evaluation Database
Among the first five batches of centralized procurement carried out by the state, CSPC won the bid for 1, 2, 9, 6 and 3 varieties respectively, with a total of 21 varieties
.
In the upcoming seventh batch of centralized procurement, CSPC has won admission tickets for 11 varieties
.
.
In the upcoming seventh batch of centralized procurement, CSPC has won admission tickets for 11 varieties
.
The competition pattern of the seventh batch of products proposed by CSPC
Source: Mi intranet database
Among the 11 varieties to be collected, the generic drugs involved in 5 varieties will have terminal sales of more than 1 billion yuan in China's public medical institutions in 2020; the competition of many varieties is becoming more intense, and there are 10 or more competing generic drugs.
There are 5
.
It is worth noting that the market share of the 10 proposed centralized procurement varieties is relatively low or blank.
If the centralized procurement is successful, the market will be opened quickly, and the company will be more willing to lower prices
.
drug drug drug enterprise enterprise enterpriseThere are 5
.
It is worth noting that the market share of the 10 proposed centralized procurement varieties is relatively low or blank.
If the centralized procurement is successful, the market will be opened quickly, and the company will be more willing to lower prices
.
R&D investment of 3.
433 billion, 50 key drug candidates
R&D investment of 3. 433 billion, 50 key drug candidates
433 billion, 50 key drug candidates
In recent years, CSPC has implemented a development strategy centered on innovation and continued to increase investment in research and development
.
In 2021, CSPC's research and development expenses will be 3.
433 billion yuan, a year-on-year increase of 18.
78%, and its research and development investment is at the forefront of domestic pharmaceutical companies
.
With huge investment, CSPC has built a rich pipeline of products under research
.
.
In 2021, CSPC's research and development expenses will be 3.
433 billion yuan, a year-on-year increase of 18.
78%, and its research and development investment is at the forefront of domestic pharmaceutical companies
.
With huge investment, CSPC has built a rich pipeline of products under research
.
Research and development expenses of CSPC (unit: 100 million yuan)
Source: Company Annual Report
At the same time, CSPC has deployed R&D centers around the world, with eight innovative research platforms including monoclonal antibody, double antibody, nano-drug, small molecule new drug screening and R&D, ADC, siRNA, mRNA, and PROTAC
.
Using the newly established nucleic acid drug development platform, CSPC is advancing research on mRNA vaccines against various strains including Delta and Omicron
.
.
Using the newly established nucleic acid drug development platform, CSPC is advancing research on mRNA vaccines against various strains including Delta and Omicron
.
On April 3, CSPC announced that the new coronavirus mRNA vaccine SYS6006 developed by the company has been approved for clinical research in China
.
The product is designed with targeted antigenic mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immune protection efficacy against the current mainstream mutant strains including Omicron and Delta; through humoral immunity and cellular immunity The body provides immune protection and can produce memory B cells to provide long-lasting protection
.
.
The product is designed with targeted antigenic mutations according to the prevalence of the strain.
Preclinical studies have shown that the product has good immune protection efficacy against the current mainstream mutant strains including Omicron and Delta; through humoral immunity and cellular immunity The body provides immune protection and can produce memory B cells to provide long-lasting protection
.
In terms of BD, CSPC has also achieved a lot.
In 2021, it will complete 6 product license introduction, cooperation and acquisition projects, involving products in multiple therapeutic areas
.
In terms of external authorization, the subsidiary NovaRock's innovative drug NBL-015 (Claudin18.
2 monoclonal antibody) has reached a cooperation with Flame Biosciences of the United States, which is an important milestone for CSPC's innovative drugs to go overseas
.
In 2021, it will complete 6 product license introduction, cooperation and acquisition projects, involving products in multiple therapeutic areas
.
In terms of external authorization, the subsidiary NovaRock's innovative drug NBL-015 (Claudin18.
2 monoclonal antibody) has reached a cooperation with Flame Biosciences of the United States, which is an important milestone for CSPC's innovative drugs to go overseas
.
At present, CSPC has about 300 research projects, including more than 40 small molecule innovative drugs, more than 40 macromolecule innovative drugs, and more than 30 new preparations, mainly focusing on tumors, immunity, respiration, neuropsychiatry, metabolism, cardiac Cerebrovascular system and anti-infective therapy
.
The company expects that more than 30 innovative drugs and new preparation products and more than 60 generic drugs will be launched in the next five years
.
.
The company expects that more than 30 innovative drugs and new preparation products and more than 60 generic drugs will be launched in the next five years
.
CSPC's key drug candidates
Source: CSPC
Among the research projects, more than 50 key drug candidates have entered the clinical or application stage
.
Among them, 13 have entered the key clinical trial stage; Rezetinib mesylate capsules (third-generation EGFR-TKI) and desvenlafaxine succinate sustained-release tablets have submitted NDAs and are expected to be approved for marketing in 2022 ; Amphotericin B liposome and irinotecan liposome injection for nano-drug injection, RANKL monoclonal antibody JMT103 will be declared for listing soon
.
.
Among them, 13 have entered the key clinical trial stage; Rezetinib mesylate capsules (third-generation EGFR-TKI) and desvenlafaxine succinate sustained-release tablets have submitted NDAs and are expected to be approved for marketing in 2022 ; Amphotericin B liposome and irinotecan liposome injection for nano-drug injection, RANKL monoclonal antibody JMT103 will be declared for listing soon
.
Data source: Minet database, company announcement
Note: The statistics are as of April 10.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
